A5112254271- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Epigenetics and DNA Methylation
- Renal and related cancers
- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Urinary Bladder and Prostate Research
- Multiple and Secondary Primary Cancers
- Tissue Engineering and Regenerative Medicine
- Prostate Cancer Diagnosis and Treatment
- Immune responses and vaccinations
- Esophageal Cancer Research and Treatment
- Cancer Research and Treatments
- Infectious Disease Case Reports and Treatments
- Urinary Tract Infections Management
- Prostate Cancer Treatment and Research
- Sexual function and dysfunction studies
- Urologic and reproductive health conditions
- Peptidase Inhibition and Analysis
- Spine and Intervertebral Disc Pathology
- Health Systems, Economic Evaluations, Quality of Life
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
Johns Hopkins University
2016-2025
Johns Hopkins Medicine
2016-2025
Johns Hopkins Hospital
2018-2025
Johns Hopkins Bayview Medical Center
2025
Bladder Cancer Advocacy Network
2019-2024
Sidney Kimmel Cancer Center
2024
Sidney Kimmel Comprehensive Cancer Center
2019-2023
University of Baltimore
2013-2022
GTx (United States)
2021
University of Southern California
2020
The antibody-drug conjugate enfortumab-vedotin acts by targeting nectin-4, a protein that is nearly ubiquitously expressed in conventional urothelial cancer. However, expression of nectin-4 morphologic variants carcinoma and nonurothelial histotypes was unknown. Immunohistochemistry for using performed on 169 patients including 83 with nonmuscle invasive bladder cancer 86 muscle Staining scored intensity (0 to 3) extent (% positive cells) the histological score system, where >15 considered...
Prior studies suggest that renal pelvic urine culture is a more accurate predictor of urosepsis. We prospectively determined the correlation between preoperative bladder cultures, intraoperative pelvis cultures and stone in patients undergoing percutaneous nephrolithotomy. also examined post-procedure risk factors for systemic inflammatory response syndrome.From February 2009 to 2011 samples from were collected Extracted stones sent analysis. Postoperatively closely monitored any signs...
Introduction: Randomized controlled trials of platinum-based neoadjuvant chemotherapy (NAC) for bladder cancer have shown that patients who achieve a pathologic response to NAC exhibit 5 y survival rates approximately 80–90% while resistant (NR) cases 30–40%. These findings highlight the need predict will benefit from conventional and plausible alternatives. Methods: The pre-treatment biopsy tissues cohort 41 with muscle invasive were treated incorporated in tissue microarray...
No AccessJournal of UrologyAdult Urology1 May 2020Multi-Institution Evaluation Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder CancerThis article is commented on by the following:Editorial Comment Ryan L. Steinberg, Lewis J. Thomas, Nathan Brooks, Sarah Mott, Andrew Vitale, Trafford Crump, Mounica Y. Rao, Marcus Daniels, Jonathan Wang, Supriya Nagaraju, William C. DeWolf, Donald Lamm, Max Kates, M. Eric Hyndman, Ashish Kamat, Trinity Bivalacqua, Kenneth...
To characterize immune cell expression among patients with non-muscle invasive bladder cancer (NMIBC) treated Bacillus Calmette-Guerin (BCG).Patients NMIBC intravesical BCG (2008-2015) were identified, and a tissue microarray was constructed using paired pre- post-BCG samples. Among undergoing BCG, cystoscopic evaluation began 3 months after initiating treatment to determine therapeutic response. IHC performed for CD8, CD4, FoxP3, PD-L1 (SP-142 22C3), PD-1. A full slide review of PD-L1+...
Abstract In addition to its role as a TB vaccine, BCG has been shown elicit heterologous protection against many other pathogens including viruses through process termed trained immunity. Despite potential broadly protective little done determine if BCG-mediated immunity levels can be optimized. Here we re-engineer express high of c-di-AMP, PAMP recognized by stimulator interferon genes (STING). We find that overexpressing c-di-AMP elicits more potent signatures higher pro-inflammatory...
Combination intravesical gemcitabine and docetaxel (GemDoce) has demonstrated efficacy as second-line therapy for patients with bacillus Calmette-Guérin (BCG)‒unresponsive nonmuscle-invasive urothelial carcinoma of the bladder (NMIBC). In context widespread BCG shortages, we performed a phase 2 prospective trial to assess GemDoce BCG-naïve NMIBC.
ABSTRACT Background The Nectin‐4 directed antibody drug conjugate enfortumab vedotin (EV) has emerged as frontline systemic therapy in combination with immune checkpoint blockade for urothelial carcinoma (UC), capitalizing on the ubiquitous expression of this protein UC. There is limited data available regarding by immunohistochemistry prostate cancer, but interest a substantial number UC patients likely to receive EV have concomitant cancer. Methods was evaluated tissue microarrays...
Study Type - Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does study add? Partial nephrectomy has become standard care for T1a renal tumours, application nephron-sparing techniques increasingly been expanded to patients with localized T1b cancers. However, relative efficacy partial versus radical these medium-sized tumours yet be definitively established. This employs a propensity scoring approach within large US population-based cohort determine that no...
No AccessJournal of UrologyAdult Urology1 Dec 2014Phase II Trial Intravesical Nanoparticle Albumin Bound Paclitaxel for the Treatment Nonmuscle Invasive Urothelial Carcinoma Bladder after bacillus Calmette-Guérin Failure James M. McKiernan, Dara D. Holder, Rashed A. Ghandour, LaMont J. Barlow, Jennifer Ahn, Max Kates, Gina Badalato, Arindam Roychoudhury, G. Joel Decastro, and Mitchell C. Benson McKiernanJames McKiernan Department Urology, Herbert Irving Cancer Center, Columbia University...
Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer preservation over radical cystectomy (RC) or those do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined Docetaxel (DOCE) has been at Johns Hopkins Hospital (JHH).To evaluate experience GEM/DOCE, to confirm safety of the regimen, identify populations that benefit most, and consider appropriate endpoints judging efficacy second line...
Intravesical bacillus Calmette-Guérin (BCG) immunotherapy is the standard of care in treating non-muscle-invasive bladder cancer, yet its mechanism action remains elusive. Both innate and adaptive immune responses have been implicated BCG activity. Although prior research has indirectly demonstrated importance T cells shown a rise CD4+ tissue after BCG, T-cell subpopulations not fully characterized. We investigated relationship between effector regulatory an competent, clinically relevant...
We used a large, population based registry to assess whether difference in overall and cardiovascular survival may exist between radical nephrectomy partial for renal cell carcinoma 2 cm or less.From the SEER (Surveillance, Epidemiology End Results) we identified 4,216 patients with histologically confirmed less who were treated nephrectomy. Patient tumor characteristics compared patient groups. Multivariate logistic regression was done predict odds of undergoing Cardiovascular cohorts,...